Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07057778
PHASE2

Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

Sponsor: Peking University People's Hospital

View on ClinicalTrials.gov

Summary

Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-07-01

Completion Date

2027-07-01

Last Updated

2025-07-10

Healthy Volunteers

No

Interventions

DRUG

Iguratimod

oral iguratimod at 25mg twice daily for 26 weeks

DRUG

low-dose rituximab

rituximab 100mg once weekly for 6 weeks

Locations (1)

Peking University Insititute of Hematology

Beijing, China